Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial involved 229 people in total, split across three groups: one group received a low dose (350 micrograms) of a medicine called dexamethasone injected into the eye, one group received a higher dose (700 micrograms), and one group received a sham (fake) procedure as a comparison. The trial was looking at a condition causing inflammation inside the eye, and the main thing being measured was how many people had no detectable eye inflammation (called a vitreous haze score of zero) at eight weeks after treatment. The reported data shows that at the eight-week mark, 35.5% of people in the low-dose group and 46.8% of people in the higher-dose group had a vitreous haze score of zero, meaning no detectable inflammation was recorded. In the sham group, 11.8% reached that same score. The reported data also shows that when it came to vision improvement — specifically, reading at least 15 more letters on an eye chart than at the start — 39.5% of the low-dose group and 42.9% of the higher-dose group reached that level, compared with 6.6% in the sham group. A separate quality-of-life questionnaire (a survey about how well people could carry out everyday visual tasks, scored from 0 to 100) showed that a meaningful improvement of at least 10 points was reported by 40.8% of the low-dose group and 50.7% of the higher-dose group, versus 15.9% of the sham group. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 23761087) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 3 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older and have been diagnosed with a long-term inflammatory eye condition called chronic intermediate uveitis in at least one eye
Who may not be able to join:
- You have a serious illness or health condition that is not currently under control
- You currently have an active infection in one or both eyes
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Medical Director, Allergan
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
1 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Patients With Vitreous Haze (Ocular Inflammation) Score of Zero
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.